Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) EBIAT (2016 - 2022)

Historic EBIAT for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to -$4.6 million.

  • Aptevo Therapeutics' EBIAT rose 2963.47% to -$4.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $7.7 million, marking a year-over-year increase of 12612.89%. This contributed to the annual value of -$18.6 million for FY2023, which is 33234.08% down from last year.
  • Aptevo Therapeutics' EBIAT amounted to -$4.6 million in Q4 2022, which was up 2963.47% from -$7.8 million recorded in Q3 2022.
  • Aptevo Therapeutics' 5-year EBIAT high stood at $28.0 million for Q2 2022, and its period low was -$13.9 million during Q1 2018.
  • For the 5-year period, Aptevo Therapeutics' EBIAT averaged around -$7.2 million, with its median value being -$7.8 million (2022).
  • As far as peak fluctuations go, Aptevo Therapeutics' EBIAT plummeted by 13317.4% in 2018, and later soared by 44734.62% in 2022.
  • Over the past 5 years, Aptevo Therapeutics' EBIAT (Quarter) stood at -$12.6 million in 2018, then increased by 12.18% to -$11.0 million in 2019, then soared by 35.0% to -$7.2 million in 2020, then increased by 8.0% to -$6.6 million in 2021, then rose by 29.63% to -$4.6 million in 2022.
  • Its EBIAT was -$4.6 million in Q4 2022, compared to -$7.8 million in Q3 2022 and $28.0 million in Q2 2022.